Extended-release trazodone in the treatment of major depressive disorder
ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, vol.20, no.5, pp.453-459, 2019 (SCI-Expanded, Scopus, TRDizin)
- Publication Type: Article / Review
- Volume: 20 Issue: 5
- Publication Date: 2019
- Doi Number: 10.5455/apd.302644467
- Journal Name: ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
- Page Numbers: pp.453-459
- Keywords: major depressive disorder, extended-release trazodone (single dose of TzCOAD per day), immediate-release trazodone (three doses of TzIR per day)
- Dokuz Eylül University Affiliated: Yes
Abstract
Major depressive disorder is a common psychiatric disorder. The aim of the treatment is to improve daily functions with remissions in symptoms, and antidepressants are the first-line treatments for a major depressive episode (moderate-severe depressive episode). In this paper, the pharmacological properties, clinical efficacy and safety of extended-release trazodone (TzCOAD) are studied. Expert opinion: A single daily dose of TzCOAD may provide similar efficacy and increased tolerability to immediate-release trazodone (TzIR) and other antidepressants.